Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Unilife Medical Solutions Limited

Wednesday, January 7, 2009 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Jan. 7 Crystal Research Associates, LLCannounced today that it has issued an Executive Informational Overview(R)(EIO(R)) on Unilife Medical Solutions Limited (UNI-ASX). The full 72-pagereport can be found at and

Unilife Medical Solutions Limited ("Unilife" or "the Company") developsand supplies innovative safety medical devices to healthcare andpharmaceutical markets. Specifically, the Company is focused on targetingpharmaceutical markets for prefilled safety syringes; healthcare markets thatmandate the use of sharps safety devices to prevent needlestick injuries; andthe U.S. medical device contract manufacturing market. Unilife has developed apatent-protected portfolio of safety syringes, with product lines includingthe Unilife Ready-to-Fill Syringe ([RTFS] hereafter referred to as the UnilifePrefilled Syringe), the Unitract(TM) 1mL Insulin and Safe Syringes, and theUnitract(TM) Clinical Range.

The key distinctive feature in all of Unilife's safety syringes is thatthe operator may control the speed of automatic needle retraction within afully integrated safety syringe. This novel combination of safety features,which Unilife does not believe is available with any other technology on themarket today, can virtually eliminate the risk of acquiring bloodborneinfections, such as the human immunodeficiency virus (HIV) or hepatitis C, vianeedlestick injuries or aerosol (blood splatter).

In July 2008, sanofi-aventis SA (SNY-NYSE) -- the world's fourth largestpharmaceutical group and largest purchaser of prefilled syringes -- signed anExclusive Agreement with Unilife, under which sanofi-aventis paid $13.9million (euro 10 million) for the right to purchase the Unilife PrefilledSyringe for five years. Sanofi-aventis is also financing Unilife's three-yearindustrialization program for the Unilife Prefilled Syringe, which could havea total value of up to $23.6 million (euro 17 million). The Company believesthat this alliance validates the strength of its proprietary technology andits competency in the development and operation of automated assembly systems.Upon the expected signing of two additional agreements with sanofi-aventis inthe next 18 months, Unilife maintains a solid cash position and projectsprofitable operations moving forward.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm thatprovides institutional-quality, fee-based research to small and mid-capcompanies. Crystal Research Associates' unique and novel product, theExecutive Informational Overview(R) (EIO(R)), is free of investment ratings,target prices, and forward-looking financial models. The EIO(R) presents acrystal clear, detailed report on a company (public or private) in a mannerthat is easily understood by the Wall Street financial community. The EIO(R)details a company's product/technology/service offerings, market size(s), keyintellectual property, leadership, growth strategy, competition, risks,financial statements, key events, and other such fundamental information.Crystal Research Associates has offices in New York City, Delray Beach,Montreal, and Toronto. Crystal Research Associates has been compensated by theCompany in cash of forty-two thousand five hundred U.S. dollars and fivehundred thousand Options/Warrants to purchase Unilife stock for its servicesin creating this report, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operatingresults, potential applications of the Company's technology, opportunities forthe Company, and any other statements about the future expectations, beliefs,goals, plans, or prospects expressed constitute forward-looking statementswithin the meaning of the Private Securities Litigation Reform Act of 1995.Any statements that are not statements of historical fact (includingstatements containing the words "will," "believes," "plans," "anticipates,""expects," "estimates," and similar expressions) should also be considered tobe forward-looking statements. There are a number of important factors thatcould cause actual results or events to differ materially from those indicatedby such forward-looking statements including, limited operating history, needfor future capital, and economic conditions generally. Additional informationon potential factors that could affect results and other risks anduncertainties are detailed from time to time in the Company's periodicreports, including forms filed with the Australian Securities Exchange (ASX).

These statements, and other forward-looking statements, are not guaranteesof future performance and involve risks and uncertainties. Crystal ResearchAssociates assumes no obligation to update any of the forward-lookingstatements in this release.

SOURCE Crystal Research Associates, LLC

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store